Subscribe

Cantargia AB (publ) (CANTA.ST)

SEK1.90 +0.02 (+1.28%)
SE STO Healthcare Biotechnology
Address Ideon Gateway 223 63
Lund, SE
CEO Hilde Hermansen Steineger
Website cantargia.com
IPO 2015-03-17
ISIN SE0006371126

Explore sections of this company profile

Description

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK1.90 +0.02 (+1.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.62
Float Shares
236.82M
Free Float %
95.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-25.34% -26.35% -42.63% -54.01% -46.96% -47.09% +56.83% -53.30% -91.94% -71.48% -74.33%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.90
DCF (Unlevered) 20.72 +992.7%
DCF (Levered) 11.91 +528.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.65
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    —
  • ✓
    EPS growth Biotechnology: +29.7%
    +167.1% ★ Q1'26: +50.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +41.1% Q1'26: -5,109.3% (vs Q1'25)
  • ✓
    EBIT margin Biotechnology: +0.0%
    +48.8% ★ Q1'26: -7,224.6% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: +609.6% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +35.4% Q1'26: +35.3% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.65) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 20.72 Current price: 1.90
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2017
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
1 EPS Ana. 		Dec 2027
2 Rev. Ana.
1 EPS Ana. 		Dec 2028
2 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana. 		Dec 2030
1 Rev. Ana.
Revenue
—
est: 4.0K (-100.0%)
—
316.70M
est: 218.40M (+45.0%)
2.93M
382.4K – 5.48M
-98.7% YoY
70.00M
9.13M – 130.87M
+2,286.4% YoY
157.50M
20.53M – 294.47M
+125.0% YoY
262.50M
34.22M – 490.78M
+66.7% YoY
178.83M
23.32M – 334.34M
-31.9% YoY
EBITDA
-453.0K
-165.05M
157.66M
est: 196.47M (-19.8%)
2.64M
344.0K – 4.93M
-98.7% YoY
62.97M
8.21M – 117.73M
+2,286.4% YoY
141.68M
18.47M – 264.89M
+125.0% YoY
236.14M
30.79M – 441.48M
+66.7% YoY
160.87M
20.97M – 300.76M
-31.9% YoY
EBIT
-60.25M
-168.47M
154.39M
est: 196.01M (-21.2%)
2.63M
343.2K – 4.92M
-98.7% YoY
62.82M
8.19M – 117.46M
+2,286.4% YoY
141.36M
18.43M – 264.28M
+125.0% YoY
235.59M
30.72M – 440.47M
+66.7% YoY
160.50M
20.93M – 300.07M
-31.9% YoY
Net Income
-60.25M
est: -125.47M (+52.0%)
-161.65M
est: -166.24M (+2.8%)
146.97M
est: 160.93M (-8.7%)
-179.25M
-749.48M – 45.91M
-211.4% YoY
-179.65M
-391.96M – 24.01M
-0.2% YoY
-137.80M
-476.70M – 29.20M
+23.3% YoY
—
— – —
+100.0% YoY
—
— – —
SGA
6.92M
14.69M
29.56M
est: 178.80M (-83.5%)
2.40M
313.1K – 4.49M
-98.7% YoY
57.31M
7.47M – 107.14M
+2,286.4% YoY
128.94M
16.81M – 241.07M
+125.0% YoY
214.90M
28.02M – 401.78M
+66.7% YoY
146.40M
19.09M – 273.71M
-31.9% YoY
EPS
-1.55
est: -0.68 (-126.9%)
-0.88
est: -0.91 (+2.8%)
0.59
est: 0.44 (+34.1%)
-1.42
-3.01 – 0.18
-421.6% YoY
-0.74
-1.58 – 0.10
+47.7% YoY
-0.90
-1.92 – 0.12
-21.6% YoY
—
— – —
+100.0% YoY
—
— – —
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-28 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-27 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-26 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-25 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-22 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-21 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-20 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-19 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-18 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-15 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-13 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-12 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-11 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-05-08 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-05-07 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-05-06 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-05-05 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-05-04 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-04-30 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-04-29 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-04-28 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-04-27 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-04-24 A 4/5 5/5 5/5 5/5 1/5 4/5 2/5
2026-04-23 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-04-22 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-04-21 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-04-20 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-04-17 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5
2026-04-16 A- 4/5 5/5 5/5 5/5 1/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-55.33M
OE per share TTM
-0.22
Owner's Yield
-10.21%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
9.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 4 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Avantis International Small Cap Value ETF AVDV 0.01% 1.37M 0.36%
2 Avantis International Small Cap Equity ETF AVDS 0.00% 9.4K 0.30%
3 Avantis International Equity ETF AVDE 0.00% 171.3K 0.23%
4 Avantis Global Small Cap Value UCITS ETF AVGS.L 0.00% 1.8K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
7.02M
Shares Outstanding
248.61M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hilde Hermansen Steineger Chief Executive Officer 4M —
Marcus Järås Founder & Scientific Advisor 355.0K male
Thoas Fioretos Founder & Scientific Advisor 355.0K male
Kjell Sjöström Founder — male
Nina Valkama Executive Assistant of Administration & Finance — female
Patrik Renblad Chief Financial Officer — male
Antonius Berkien Chief Business Officer — male
Wolfram C. Dempke Chief Medical Officer — —
David Liberg Chief Scientific Officer — —
Johanna Christensen Financial Controller — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology